⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383168 | 1.00 | — | — | |
| SCHEMBL93984 | 1.00 | — | — | |
| SCHEMBL6081094 | 0.92 | — | — | |
| SCHEMBL6377549 | 0.92 | — | — | |
| SCHEMBL6377749 | 0.89 | — | — | |
| SCHEMBL6376345 | 0.88 | TRPV1 (0.61) | — | |
| SCHEMBL947521 | 0.88 | — | — | |
| SCHEMBL6301875 | 0.88 | — | — | |
| SCHEMBL6301871 | 0.87 | — | — | |
| SCHEMBL6304951 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | claimed |
| EP-4118070-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4054559-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4055018-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054336-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054586-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |